Answers are grounded in this paper and cite their sources.
Background: Studies have reported that Cyclophilin A (CyPA) has the potential to be a valuable biomarker of coronary artery disease (CAD). It was found that plasma levels of CyPA correlated with the anatomical severity of CAD. Several issues remain regarding the role of CyPA as a biomarker of CAD. An attempt is made to study correlation of plasma CyPAlevels with severity of coronary artery disease and traditional coronary risk factors. Methods: 404 patients aged ≥ 18 years of either gender with chest pain undergoing coronary angiography (CAG) were included. They were subjected to standard clinical evaluation, estimation of plasma CyPA by enzyme linked immunosorbent assay (ELISA) method and CAG. Plasma CyPA levels were compared with CAG and traditional coronary risk factors. Qualitative and quantitative variables were tested using ChiSquare test and Mann Whitney U test respectively. The cut off values of CyPA across the angiographic groups were calculated using Receiver Operating Characteristic (ROC) curve. The predictive signicance of CyPA and risk factors in detecting signicant CAD was tested using sensitivity, specicity, positive predictive value (PPV) and negative predictive value (NPV). Results: Median CyPA levels were signicantly higher in obstructive CAD (15.8 ng/ml) as compared non-obstructive CAD (7.8 ng/ml) and normal coronary arteries (6.0 ng/ml). Plasma CyPA levels of >8.0 ng/mL, >9.4 ng/mL and >13.0 ng/mL reliably predicted presence of CAD, obstructive CAD and risk of ACS respectively with excellent specicity and good sensitivity. Plasma CyPAlevels were signicantly higher in males, diabetic patients, patients with dyslipidemia, and smokers. Conclusion: Plasma CyPAis a novel biomarker for CAD
No takes yet. Share an insight, caveat, or question.
Ajeya Ukadgaonkar (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: